SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
NCT ID: NCT04381468
Last Updated: 2024-08-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-07-22
Study Completion Date
2024-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
NCT03828747
Alzheimer's Disease
COMPLETED
PHASE2
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
NCT03703856
Alzheimer Disease
ACTIVE_NOT_RECRUITING
PHASE4
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
NCT03289143
Alzheimer's Disease
TERMINATED
PHASE2
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
NCT02624778
Alzheimer Disease
COMPLETED
PHASE1
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
NCT03462121
Mild to Moderate Dementia Due to Alzheimer's Disease
With or Without Coexisting Cerebrovascular Disease
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab, administered as IV infusions every 4 weeks for 44 weeks (12 infusions) in mild dementia due to Alzheimer's Disease (AD)) participants. Participants will be randomized 1:1 to receive 40 mg/kg pepinemab or placebo.
This is a randomized double-blind, placebo-controlled study of pepinemab in mild dementia due to AD. The study is 52 weeks in duration, including a safety and efficacy evaluation 4 weeks after the last dose of study drug. Participants with resolved adverse events at Week 48 will have a safety telephone call at Week 52. Participants with unresolved adverse events at Week 48 will have a safety in-office visit at Week 52. The study protocol will include two sentinel participants in each of the two blinded dose arms. Sentinel dosing will be implemented by randomly assigning one study participant to one of the two dose arms in a blinded manner, treating those participants with study drug. If no unexpected serious adverse events are observed within 48 hours after the first and second participants receive treatment, two additional participants will be enrolled, with one participant assigned randomly to each of the two dose arms. Again a 48-hour safety period will be observed following treatment of the fourth participant to document any unexpected safety events that may occur. Should no unexpected serious adverse events occur within 48 hours after the third and fourth participants receive treatment, the remaining participants will be assigned to the study dose arms according to the blinded randomization scheme and the 1:1 randomization ratio. Participants will be randomized to one of two treatment arms and will receive one dose of study drug every 4 weeks during the 44-week dosing period for a total of 12 doses of study drug. The primary objective is the safety and tolerability of study drug. A key secondary objective is the change in brain metabolism as assessed by \[18F\]fluorodeoxyglucose (FDG)-PET in the resting state.
This is a randomized double-blind, placebo-controlled study of pepinemab in mild dementia due to AD. The study is 52 weeks in duration, including a safety and efficacy evaluation 4 weeks after the last dose of study drug. Participants with resolved adverse events at Week 48 will have a safety telephone call at Week 52. Participants with unresolved adverse events at Week 48 will have a safety in-office visit at Week 52. The study protocol will include two sentinel participants in each of the two blinded dose arms. Sentinel dosing will be implemented by randomly assigning one study participant to one of the two dose arms in a blinded manner, treating those participants with study drug. If no unexpected serious adverse events are observed within 48 hours after the first and second participants receive treatment, two additional participants will be enrolled, with one participant assigned randomly to each of the two dose arms. Again a 48-hour safety period will be observed following treatment of the fourth participant to document any unexpected safety events that may occur. Should no unexpected serious adverse events occur within 48 hours after the third and fourth participants receive treatment, the remaining participants will be assigned to the study dose arms according to the blinded randomization scheme and the 1:1 randomization ratio. Participants will be randomized to one of two treatment arms and will receive one dose of study drug every 4 weeks during the 44-week dosing period for a total of 12 doses of study drug. The primary objective is the safety and tolerability of study drug. A key secondary objective is the change in brain metabolism as assessed by \[18F\]fluorodeoxyglucose (FDG)-PET in the resting state.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Participants will be randomized to one of two treatment arms and will receive one dose of study drug every 4 weeks during the 44-week dosing period for a total of 12 doses of study drug
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pepinemab 40mg/kg
The study drug, pepinemab, will be administered via monthly intravenous infusions.
Group Type
EXPERIMENTAL
Pepinemab
Intervention Type
DRUG
Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Placebo
.A placebo control will be administered via monthly intravenous infusions.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Intervention Type
DRUG
Pepinemab
Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Written informed consent from the participant and legally acceptable representative (trial partner).
2. Have a reliable and competent trial partner who must have a close relationship with the participant, who has face to face contact at least three days a week for a minimum of ten waking hours a week and is willing to accompany the participant to all trial visits. The trial partner should understand the nature of the trial and adhere to trial requirements (e.g., dose, visit schedules, receive phone calls, and evaluations).
3. Male and female participants between the ages of 55 to 85 (inclusive).
4. If female, not be of childbearing potential as indicated by one of the following:
a. Has reached natural menopause defined as either: i. ≥ 12 months of spontaneous amenorrhea or ii. ≥ 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels \> 40 mIU/ml as determined by the central laboratory; b. Has had a hysterectomy; or c. Has had a bilateral tubal ligation; or d. Has had a bilateral oophorectomy (with or without a hysterectomy) and more than 6 weeks have passed since the surgery.
5. If male, must agree to use a reliable method of birth control (condoms with contraceptive forms or sexual abstinence) during the study and for 6 months after the last dose of study drug.
6. Must fulfill one of the following:
1. A documented amyloid PET scan (florbetaben F18, florbetapir F18, or flutametamol F18) determined as positive by the Investigator obtained at any time prior to the Screening visit; or
2. A documented positive amyloid CSF result obtained at any time prior to the Screening visit; or
3. Investigator has knowledge of positive amyloid PET scan or positive amyloid CSF result obtained previously; or
4. A positive amyloid CSF result at screening. The cut-off value for CSF Aβ1-42 or CSF Aβ1-42/Aβ1-40 ratio will be based on the value determined by Vaccinex
7. Evidence of cognitive impairment based on history and neuropsychological testing that meet the diagnostic criteria for probable Alzheimer's dementia.
8. Global Clinical Dementia Rating (CDR) of 0.5 or 1.0
9. MMSE score of 17-26, inclusive.
10. Adequate vision, hearing, and motor function to comply with testing.
11. If receiving medications for AD (including but not limited to donepezil, rivastigmine, galantamine, tacrine, and memantine), be on a stable dose for at least 8 weeks prior to Screening Visit.
12. If on stable doses of centrally-acting medications, be on a stable dose for 8 weeks prior to Screening Visit.
13. In the opinion of the Investigator, is in reasonably good health over the last 6 months and any chronic disease is stable based on medical history and screening assessments.
Exclusion
1. Inability to comply with visit schedule or other protocol requirements.
2. Have participated in an investigational drug or device study within 30 days of the Baseline Visit. If previous investigational drug was a monoclonal antibody, antibody-drug conjugate, or similar protein therapeutic, 180 days or 5 half-lives, whichever occurs first.
3. Have a known allergy to any ingredient in the study drug formulation.
4. Have a body weight greater than 125 kg.
5. Are a suicide risk, as determined by meeting any of the following criteria:
1. Suicide attempt within one year prior to the Baseline Visit.
2. Suicidal ideation as defined by a positive response to question 4 and 5 on the C-SSRS within 60 days of the Baseline Visit.
6. Have a history of substance abuse (based on DSMIV criteria) within the past 12 months prior to Screening.
7. Significant acute or chronic infection at Screening including, among others: Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (defined as, HBV surface antigen positive or positive HCV antibody with reflex to positive HCV RNA) at Screening.
8. Have clinically significant laboratory or ECG abnormalities at Screening in the opinion of the Investigator.
9. Have clinically relevant hematologic, hepatic, cardiac, or renal disease.
10. Have a clinically significant medical, surgical, laboratory, or behavioral abnormality which in the judgment of the Investigator makes the participant unsuitable for the study, as well as anyone with a history of malignancy of any type within 2 years of Screening. Persons with a history of surgically excised non-melanoma skin cancers, superficial bladder or prostate cancer are permitted.
11. Participants who have a diagnosis of a neurological condition causing cognitive impairment other than sporadic mild dementia due to AD (e.g., Lewy body disease or frontotemporal dementia), a primary psychiatric diagnosis (e.g., Cognitive Impairment due to Schizophrenia, CIAS), history of frequent concussions or significant findings on brain MRI at screening inconsistent with AD (e.g., cerebrovascular disease or tumor).
12. Have any of the following conditions (which would exclude MRI or PET participation):
1. Participants deemed unable to cooperate due to claustrophobia, inability to lie on scanner bed for 45 minutes, or inability to achieve venous access sufficient for tracer or pepinemab administration.
2. An implant/device/condition that is contraindicated for MRI (e.g., pacemaker, severe claustrophobia, prosthetic heart valve, any metal fragments in the eyes or body--in some cases, an X-ray may be needed before an MRI scan, to ensure it is safe to enter the scanner).
3. Body habitus that would impede completion of imaging scans.
13. Has an MRI scan obtained at Screening that shows evidence of a neurological disorder other than early AD or \> 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"), a single area of superficial siderosis,
14. Any other clinically significant finding on MRI (e.g., any lesion that may account for their cognitive impairment, including but not limited to brain tumor, severe white matter disease arteriovenous malformation, cavernous hemangioma, or any infarct in a strategic cortical or subcortical location).
15. Are undergoing FDG-PET and have received research-related radiation exposure that exceeds institutional guidelines in the prior year if applicable.
16. Are undergoing a LP for CSF collection and have any of the following conditions: uncorrected bleeding or clotting disorders, skin infections near the site of the LP, suspicion of increased intracranial pressure, allergies to numbing medications (local anesthetics), acute spinal trauma.
17. Are undergoing a LP for CSF collection and taking any of the following types of anticoagulants: coumarins and indandiones, Factor Xa inhibitors, heparins, or thrombin inhibitors.
18. Has received treatment with any FDA accelerated approval therapy for treatment of Alzheimer's Disease
19. Has a Screening MRI that shows Amyloid-related imaging abnormalities edema (ARIA-E)
2. Have a reliable and competent trial partner who must have a close relationship with the participant, who has face to face contact at least three days a week for a minimum of ten waking hours a week and is willing to accompany the participant to all trial visits. The trial partner should understand the nature of the trial and adhere to trial requirements (e.g., dose, visit schedules, receive phone calls, and evaluations).
3. Male and female participants between the ages of 55 to 85 (inclusive).
4. If female, not be of childbearing potential as indicated by one of the following:
a. Has reached natural menopause defined as either: i. ≥ 12 months of spontaneous amenorrhea or ii. ≥ 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels \> 40 mIU/ml as determined by the central laboratory; b. Has had a hysterectomy; or c. Has had a bilateral tubal ligation; or d. Has had a bilateral oophorectomy (with or without a hysterectomy) and more than 6 weeks have passed since the surgery.
5. If male, must agree to use a reliable method of birth control (condoms with contraceptive forms or sexual abstinence) during the study and for 6 months after the last dose of study drug.
6. Must fulfill one of the following:
1. A documented amyloid PET scan (florbetaben F18, florbetapir F18, or flutametamol F18) determined as positive by the Investigator obtained at any time prior to the Screening visit; or
2. A documented positive amyloid CSF result obtained at any time prior to the Screening visit; or
3. Investigator has knowledge of positive amyloid PET scan or positive amyloid CSF result obtained previously; or
4. A positive amyloid CSF result at screening. The cut-off value for CSF Aβ1-42 or CSF Aβ1-42/Aβ1-40 ratio will be based on the value determined by Vaccinex
7. Evidence of cognitive impairment based on history and neuropsychological testing that meet the diagnostic criteria for probable Alzheimer's dementia.
8. Global Clinical Dementia Rating (CDR) of 0.5 or 1.0
9. MMSE score of 17-26, inclusive.
10. Adequate vision, hearing, and motor function to comply with testing.
11. If receiving medications for AD (including but not limited to donepezil, rivastigmine, galantamine, tacrine, and memantine), be on a stable dose for at least 8 weeks prior to Screening Visit.
12. If on stable doses of centrally-acting medications, be on a stable dose for 8 weeks prior to Screening Visit.
13. In the opinion of the Investigator, is in reasonably good health over the last 6 months and any chronic disease is stable based on medical history and screening assessments.
Exclusion
1. Inability to comply with visit schedule or other protocol requirements.
2. Have participated in an investigational drug or device study within 30 days of the Baseline Visit. If previous investigational drug was a monoclonal antibody, antibody-drug conjugate, or similar protein therapeutic, 180 days or 5 half-lives, whichever occurs first.
3. Have a known allergy to any ingredient in the study drug formulation.
4. Have a body weight greater than 125 kg.
5. Are a suicide risk, as determined by meeting any of the following criteria:
1. Suicide attempt within one year prior to the Baseline Visit.
2. Suicidal ideation as defined by a positive response to question 4 and 5 on the C-SSRS within 60 days of the Baseline Visit.
6. Have a history of substance abuse (based on DSMIV criteria) within the past 12 months prior to Screening.
7. Significant acute or chronic infection at Screening including, among others: Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (defined as, HBV surface antigen positive or positive HCV antibody with reflex to positive HCV RNA) at Screening.
8. Have clinically significant laboratory or ECG abnormalities at Screening in the opinion of the Investigator.
9. Have clinically relevant hematologic, hepatic, cardiac, or renal disease.
10. Have a clinically significant medical, surgical, laboratory, or behavioral abnormality which in the judgment of the Investigator makes the participant unsuitable for the study, as well as anyone with a history of malignancy of any type within 2 years of Screening. Persons with a history of surgically excised non-melanoma skin cancers, superficial bladder or prostate cancer are permitted.
11. Participants who have a diagnosis of a neurological condition causing cognitive impairment other than sporadic mild dementia due to AD (e.g., Lewy body disease or frontotemporal dementia), a primary psychiatric diagnosis (e.g., Cognitive Impairment due to Schizophrenia, CIAS), history of frequent concussions or significant findings on brain MRI at screening inconsistent with AD (e.g., cerebrovascular disease or tumor).
12. Have any of the following conditions (which would exclude MRI or PET participation):
1. Participants deemed unable to cooperate due to claustrophobia, inability to lie on scanner bed for 45 minutes, or inability to achieve venous access sufficient for tracer or pepinemab administration.
2. An implant/device/condition that is contraindicated for MRI (e.g., pacemaker, severe claustrophobia, prosthetic heart valve, any metal fragments in the eyes or body--in some cases, an X-ray may be needed before an MRI scan, to ensure it is safe to enter the scanner).
3. Body habitus that would impede completion of imaging scans.
13. Has an MRI scan obtained at Screening that shows evidence of a neurological disorder other than early AD or \> 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"), a single area of superficial siderosis,
14. Any other clinically significant finding on MRI (e.g., any lesion that may account for their cognitive impairment, including but not limited to brain tumor, severe white matter disease arteriovenous malformation, cavernous hemangioma, or any infarct in a strategic cortical or subcortical location).
15. Are undergoing FDG-PET and have received research-related radiation exposure that exceeds institutional guidelines in the prior year if applicable.
16. Are undergoing a LP for CSF collection and have any of the following conditions: uncorrected bleeding or clotting disorders, skin infections near the site of the LP, suspicion of increased intracranial pressure, allergies to numbing medications (local anesthetics), acute spinal trauma.
17. Are undergoing a LP for CSF collection and taking any of the following types of anticoagulants: coumarins and indandiones, Factor Xa inhibitors, heparins, or thrombin inhibitors.
18. Has received treatment with any FDA accelerated approval therapy for treatment of Alzheimer's Disease
19. Has a Screening MRI that shows Amyloid-related imaging abnormalities edema (ARIA-E)
Minimum Eligible Age
55 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alzheimer's Drug Discovery Foundation
OTHER
Sponsor Role
collaborator
Alzheimer's Association
OTHER
Sponsor Role
collaborator
Vaccinex Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Siemers, MD
Role: STUDY_DIRECTOR
Vaccinex Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pacific Research Network, Inc
San Diego, California, United States
Site Status
Georgetown University
Washington D.C., District of Columbia, United States
Site Status
Brain Matters Research
Delray Beach, Florida, United States
Site Status
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida, United States
Site Status
JEM Research Institute
Lake Worth, Florida, United States
Site Status
Premiere Research Institute of Palm Beach, Neurology
Palm Beach, Florida, United States
Site Status
Brain Matters Research
Stuart, Florida, United States
Site Status
Indiana University School of Medicine
Indianapolis, Indiana, United States
Site Status
University of Kansas Medical Center
Fairway, Kansas, United States
Site Status
Neurological Associates of Albany
Albany, New York, United States
Site Status
Dent Neurological Associates
Amherst, New York, United States
Site Status
Columbia University Irving Medical Center
New York, New York, United States
Site Status
University of Rochester Medical Center
Rochester, New York, United States
Site Status
Re-Cognition Health
Fairfax, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992 Apr 10;256(5054):184-5. doi: 10.1126/science.1566067. No abstract available.
Reference Type
BACKGROUND
Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011 Sep 7;17(9):1060-5. doi: 10.1038/nm.2460.
Reference Type
BACKGROUND
Moreau-Fauvarque C, Kumanogoh A, Camand E, Jaillard C, Barbin G, Boquet I, Love C, Jones EY, Kikutani H, Lubetzki C, Dusart I, Chedotal A. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J Neurosci. 2003 Oct 8;23(27):9229-39. doi: 10.1523/JNEUROSCI.23-27-09229.2003.
Reference Type
BACKGROUND
Fisher, T. L., J. E. Leonard, and E. Smith. 2019. Investigator's Brochure : pepinemab-Neurology. Version 4 ed. Vaccinex, Inc.
Reference Type
BACKGROUND
Basile JR, Gavard J, Gutkind JS. Plexin-B1 utilizes RhoA and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J Biol Chem. 2007 Nov 30;282(48):34888-95. doi: 10.1074/jbc.M705467200. Epub 2007 Sep 12.
Reference Type
BACKGROUND
Giraudon P, Vincent P, Vuaillat C, Verlaeten O, Cartier L, Marie-Cardine A, Mutin M, Bensussan A, Belin MF, Boumsell L. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol. 2004 Jan 15;172(2):1246-55. doi: 10.4049/jimmunol.172.2.1246.
Reference Type
BACKGROUND
Giraudon P, Vincent P, Vuaillat C. T-cells in neuronal injury and repair: semaphorins and related T-cell signals. Neuromolecular Med. 2005;7(3):207-16. doi: 10.1385/NMM:7:3:207.
Reference Type
BACKGROUND
Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, Toyofuku T, Nakagawa Y, Kang S, Friedel RH, Sakoda S, Kikutani H, Kumanogoh A. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 2010 Feb 1;184(3):1499-506. doi: 10.4049/jimmunol.0903302. Epub 2009 Dec 28.
Reference Type
BACKGROUND
Smith ES, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, Klimatcheva E, Mallow C, Cornelius C, Leonard JE, Marchi N, Janigro D, Argaw AT, Pham T, Seils J, Bussler H, Torno S, Kirk R, Howell A, Evans EE, Paris M, Bowers WJ, John G, Zauderer M. SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis. 2015 Jan;73:254-68. doi: 10.1016/j.nbd.2014.10.008. Epub 2014 Oct 18.
Reference Type
BACKGROUND
Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. Body weight is modulated by levels of full-length huntingtin. Hum Mol Genet. 2006 May 1;15(9):1513-23. doi: 10.1093/hmg/ddl072. Epub 2006 Mar 28.
Reference Type
BACKGROUND
Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet. 2005 Dec 15;14(24):3823-35. doi: 10.1093/hmg/ddi407. Epub 2005 Nov 8.
Reference Type
BACKGROUND
Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol Dis. 2011 Jul;43(1):257-65. doi: 10.1016/j.nbd.2011.03.018. Epub 2011 Mar 31.
Reference Type
BACKGROUND
Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, Zauderer M, Hayden MR. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2015 Apr;76:46-56. doi: 10.1016/j.nbd.2015.01.002. Epub 2015 Feb 3.
Reference Type
BACKGROUND
Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK. Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15;22(4):827-36. doi: 10.1158/1078-0432.CCR-15-0431. Epub 2015 Oct 7.
Reference Type
BACKGROUND
LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, Stone L, Mattson D, Galluzzi A, Fisher TL, Reilly C, Winter LA, Leonard JE, Zauderer M. Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e367. doi: 10.1212/NXI.0000000000000367. eCollection 2017 Jul.
Reference Type
BACKGROUND
Verkhratsky A, Zorec R, Parpura V. Stratification of astrocytes in healthy and diseased brain. Brain Pathol. 2017 Sep;27(5):629-644. doi: 10.1111/bpa.12537.
Reference Type
BACKGROUND
Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. J Neurosci. 2011 Nov 9;31(45):16064-9. doi: 10.1523/JNEUROSCI.4158-11.2011.
Reference Type
BACKGROUND
Saab AS, Tzvetavona ID, Trevisiol A, Baltan S, Dibaj P, Kusch K, Mobius W, Goetze B, Jahn HM, Huang W, Steffens H, Schomburg ED, Perez-Samartin A, Perez-Cerda F, Bakhtiari D, Matute C, Lowel S, Griesinger C, Hirrlinger J, Kirchhoff F, Nave KA. Oligodendroglial NMDA Receptors Regulate Glucose Import and Axonal Energy Metabolism. Neuron. 2016 Jul 6;91(1):119-32. doi: 10.1016/j.neuron.2016.05.016. Epub 2016 Jun 9.
Reference Type
BACKGROUND
Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006 Jun 2;312(5778):1389-92. doi: 10.1126/science.1123511.
Reference Type
BACKGROUND
Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008 Mar;11(3):251-3. doi: 10.1038/nn2047. Epub 2008 Feb 3.
Reference Type
BACKGROUND
Benraiss A, Wang S, Herrlinger S, Li X, Chandler-Militello D, Mauceri J, Burm HB, Toner M, Osipovitch M, Jim Xu Q, Ding F, Wang F, Kang N, Kang J, Curtin PC, Brunner D, Windrem MS, Munoz-Sanjuan I, Nedergaard M, Goldman SA. Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun. 2016 Jun 7;7:11758. doi: 10.1038/ncomms11758.
Reference Type
BACKGROUND
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5.
Reference Type
BACKGROUND
Gonzalez-Reyes RE, Nava-Mesa MO, Vargas-Sanchez K, Ariza-Salamanca D, Mora-Munoz L. Involvement of Astrocytes in Alzheimer's Disease from a Neuroinflammatory and Oxidative Stress Perspective. Front Mol Neurosci. 2017 Dec 19;10:427. doi: 10.3389/fnmol.2017.00427. eCollection 2017.
Reference Type
BACKGROUND
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013 Jan 10;368(2):107-16. doi: 10.1056/NEJMoa1211103. Epub 2012 Nov 14.
Reference Type
BACKGROUND
Walter J. The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases. J Biol Chem. 2016 Feb 26;291(9):4334-41. doi: 10.1074/jbc.R115.704981. Epub 2015 Dec 22.
Reference Type
BACKGROUND
Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016 May 6;352(6286):712-716. doi: 10.1126/science.aad8373. Epub 2016 Mar 31.
Reference Type
BACKGROUND
Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med. 2007 Feb;13(2):54-63. doi: 10.1016/j.molmed.2006.12.005. Epub 2007 Jan 4.
Reference Type
BACKGROUND
Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron. 2008 Nov 6;60(3):430-40. doi: 10.1016/j.neuron.2008.10.013.
Reference Type
BACKGROUND
Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller L, Huang H, Klimatcheva E, Howell A, Kirk R, Evans E, Paris M, Leonard JE, Smith ES, Zauderer M. Generation and preclinical characterization of an antibody specific for SEMA4D. MAbs. 2016;8(1):150-62. doi: 10.1080/19420862.2015.1102813. Epub 2015 Oct 2.
Reference Type
BACKGROUND
Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q. Role of Blood-Brain Barrier in Alzheimer's Disease. J Alzheimers Dis. 2018;63(4):1223-1234. doi: 10.3233/JAD-180098.
Reference Type
BACKGROUND
Reiman EM, Jagust WJ. Brain imaging in the study of Alzheimer's disease. Neuroimage. 2012 Jun;61(2):505-16. doi: 10.1016/j.neuroimage.2011.11.075. Epub 2011 Dec 7.
Reference Type
BACKGROUND
Lange C, Suppa P, Frings L, Brenner W, Spies L, Buchert R. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion. J Alzheimers Dis. 2016;49(4):945-959. doi: 10.3233/JAD-150814.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VX15/2503-11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
NCT05696483
ENROLLING_BY_INVITATION
PHASE1
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
NCT00322153
COMPLETED
PHASE3
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
NCT00454870
COMPLETED
PHASE2
SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.
NCT02036645
COMPLETED
PHASE1
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
NCT00257673
COMPLETED
PHASE2
Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE
NCT07107074
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616
COMPLETED
PHASE2
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
NCT00722046
COMPLETED
PHASE2
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616
RECRUITING
PHASE2
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
NCT00566397
COMPLETED
PHASE2
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
NCT04311515
TERMINATED
PHASE2
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
NCT06402838
ACTIVE_NOT_RECRUITING
PHASE2
HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)
NCT02013310
COMPLETED
PHASE2
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
NCT02626572
COMPLETED
PHASE2
Metformin in Alzheimer's Dementia Prevention
NCT04098666
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo
NCT01827982
COMPLETED
PHASE1
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
NCT00842673
COMPLETED
PHASE2
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
NCT02008357
COMPLETED
PHASE3
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
NCT00359944
COMPLETED
PHASE2
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
NCT04669028
COMPLETED
PHASE3
A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition
NCT01044342
COMPLETED
PHASE1
Study of AV-1959D, an Amyloid Beta Vaccine
NCT05642429
ACTIVE_NOT_RECRUITING
PHASE1
A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects
NCT03935568
TERMINATED
PHASE1
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
NCT00574132
COMPLETED
PHASE3